Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-486-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0022H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Whole blood

Sample Requirements

10 µl/well

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

25 – 0.78 amol/μl

Limit of Detection

0.26 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 4.1%

Inter-assay (Run-to-Run)

n = 5,
CV = 8.1%

Spiking Recovery

87.6%

Dilutation Linearity

96.8%

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-486-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Oncology

Summary

MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

hsa-miR-486-5p is located on the chromosome 8, in the region which contains potential tumor-suppressor genes and is often deleted in various types of tumors. hsa-miR-486-5p gene was first cloned from the fetal liver. Reduced miR‑486-5p expression is a frequent molecular event in human malignancies.

Deregulation of cancer-related miR-486-5p is a common event in both benign and malignant human breast tumors. miR-486-5p is one of the most downregulated miRNAs in lung tumor tissues. Its decreased level in circulation indicates lung cancer progression and metastasis. Thus, serum miR-486-5p has a great potential to serve as a marker in clinical diagnosis of lung cancers. Several studies have also shown aberrant miR-486-5p expression and its prognostic value in digestive system cancers. miR-486-5p may become a novel target in treatment of patients with gastric cancers. Other cancer types associated with deregulated miR-486-5p levels are hepatocellular carcinomas and prostate cancer.

References to Summary

References to miR-486-5p

  • WANG, J., et al. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene, 2014, 33.9: 1181.
  • ZHU, Jianjie, et al. Expression profile analysis of microRNAs and downregulated miR-486-5p and miR-30a-5p in non-small cell lung cancer. Oncology reports, 2015, 34.4: 1779-1786.
  • TAHIRI, Andliena, et al. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis, 2013, 35.1: 76-85.
  • LI, Ying; LIANG, Li; ZHANG, Chun-yang. Isothermally sensitive detection of serum circulating miRNAs for lung cancer diagnosis. Analytical chemistry, 2013, 85.23: 11174-11179.
  • TIAN, Fei, et al. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer. Gene, 2016, 591.2: 338-343.
  • CHEN, Hui, et al. Expression and prognostic value of miR-486-5p in patients with gastric adenocarcinoma. PLoS One, 2015, 10.3: e0119384.
  • REN, Chuanli, et al. miR-486-5p expression pattern in esophageal squamous cell carcinoma, gastric cancer and its prognostic value. Oncotarget, 2016, 7.13: 15840.
  • HUANG, Xin‐Ping, et al. MicroRNA‐486‐5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1. The FEBS journal, 2015, 282.3: 579-594.
  • YANG, Yang, et al. The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways. Oncotarget, 2017, 8.42: 72835.
Related Products Documents